The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Neuland Laboratories's share price is ₹18786.00.
Neuland Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,576.65. Hence, Neuland Laboratories's PS Ratio for today is 11.92.
The historical rank and industry rank for Neuland Laboratories's PS Ratio or its related term are showing as below:
NSE:NEULANDLAB'
s PS Ratio Range Over the Past 10 Years
Min: 0.46 Med: 2.36 Max: 15.49
Current: 11.46
During the past 13 years, Neuland Laboratories's highest PS Ratio was 15.49. The lowest was 0.46. And the median was 2.36.
NSE:NEULANDLAB's PS Ratio is ranked worse than 88.95% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.27
vs NSE:NEULANDLAB: 11.46
Neuland Laboratories Ltd has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Neuland Laboratories was 37.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 20.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 17.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 12.00% per year.
During the past 13 years, Neuland Laboratories's highest 3-Year average Revenue per Share Growth Rate was 20.30% per year. The lowest was -8.10% per year. And the median was 10.50% per year.
Back to Basics: PS Ratio
Neuland Laboratories (NSE:NEULANDLAB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Neuland Laboratories PS Ratio Related Terms
Neuland Laboratories PS Ratio Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's PS Ratio distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Neuland Laboratories's Share Price of today is ₹18786.00. Neuland Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,576.65.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Neuland Laboratories (NSE:NEULANDLAB) has a PS Ratio of 11.92 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Neuland Laboratories and its competitors. This is 405% above median its historical median of 2.36. Over the past decade, Neuland Laboratories' PS Ratio has ranged from 0.46 to 15.49. According to the industry distribution chart, Neuland Laboratories ranks #845 out of 950 companies in the Drug Manufacturers industry, placing it in the top 88.9%.
Is Neuland Laboratories' PS Ratio too high?
Neuland Laboratories' current PS Ratio of 11.92 is 405% above median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 15.49. The Drug Manufacturers industry median PS Ratio is 2.27. Neuland Laboratories' value of 11.92 is 425.1% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #845 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #845 out of 950 companies for PS Ratio. This places Neuland Laboratories in the lower half of its industry. The industry median PS Ratio is 2.27. Neuland Laboratories' value of 11.92 is 425.1% above this benchmark. Historically, Neuland Laboratories' own PS Ratio has ranged from 0.46 to 15.49 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 2.27, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.27, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current PS Ratio of 11.92 is 425.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current PS Ratio is 11.92, which is 405% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,510.11, compared to a current price of ₹18,786.00 — trading 13.8% above its estimated fair value. The current PS Ratio is 11.92, which is 405% above median its 10-year median of 2.36 and 425.1% above the Drug Manufacturers industry median of 2.27. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current PS Ratio is 11.92 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹18,786.00 is trading 13.8% above its estimated GF Value™ of ₹16,510.11.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
PS Ratio: 11.92 (405% above median its 10-year median of 2.36)
GF Value™: ₹16,510.11 vs. price of ₹18,786.00 (13.8% above fair value)
Industry Position: 425.1% above the Drug Manufacturers median (#845 of 950)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
